Laboratorios Farmaceuticos Rovi

Historical price data

Laboratorios Farmaceuticos Rovi is a publicly traded Spanish pharmaceutical company with a dual business model combining proprietary drug development and contract manufacturing. The company has demonstrated significant growth, reporting €743.5 million in operating revenue for 2025, driven by its specialty pharmaceuticals and CDMO segments. Rovi is strategically investing in R&D, with expenses increasing 47% in 2025, and has established key international partnerships, including a major collaboration with Roche. Its operations span over 60 countries, supported by four manufacturing plants.

Proprietary expertise in Low Molecular Weight Heparin (LMWH) development and advanced manufacturing technologies for sterile fill-finish (prefilled syringes) and oral solid dosage forms.

Rovi competes in specialty pharma against mid-cap European firms and global generics/biosimilar companies, and in CDMO against large global contractors and specialized European manufacturers. Its differentiation stems from an integrated business model, deep heparin expertise, and a focus on complex drug delivery systems like prefilled syringes.